Antengene’s Eltanexor (ATG-016) Receive the NMPA’s IND Approval for P-II Study to Treat Patients with High-Risk Myelodysplastic Syndromes
- The NMPA has approved a P-II open-label study to evaluate the safety, tolerability & efficacy of SINE compound (ATG-016) in patients with high-risk MDS
- The ongoing P-I/II (KCP-8602-801) trial evaluated the safety, tolerability, and efficacy of ATG-016 in patients of 6 sub-parts of r/r cancer indications initiated by Karyopharm
- The company will take part in the Part F P-II (KCP-8602-801) study for high-risk MDS patients while the Part F P-I study showed an ORR of 53% and m-OS of 9.86mos. in efficacy-evaluable patients. ATG-016 has received ODD from the US FDA for MDS & is currently evaluating in the (HATCH) study, P-I/II (REACH) registration-track study & P-I/II for advanced solid tumors
Ref: PR Newswire | Image: Antengene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].